Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218917 · ClinicalTrials.gov registry record · Phase 2
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
A Phase 2 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT03218917 is a Phase 2 study that has completed, run by Insmed Incorporated. The registered enrollment target is 256 participants.
The verdict
NCT03218917, a Phase 2 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
Interventions
- DRUG Placebo
- DRUG Brensocatib 10 mg
- DRUG Brensocatib 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218917
The ClinicalTrials.gov registry entry for NCT03218917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03218917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03218917 about?
NCT03218917 is a clinical study titled "Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis". The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
What is the current status of trial NCT03218917?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2017-10-31. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT03218917?
The interventions under investigation include: Placebo (DRUG), Brensocatib 10 mg (DRUG), Brensocatib 25 mg (DRUG).
Who is sponsoring clinical trial NCT03218917?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.